Artiva Biotherapeutics, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDArtiva Biotherapeutics, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 91), indicating clear outperformance against the broad market. Earnings contraction of 14% provides fundamental context to the price action. Investors should exercise caution due to high volatility (150% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $8.33 | +15.51% | ABOVE |
| 50 SMA | $9.49 | +1.42% | ABOVE |
| 100 SMA | $7.52 | +27.98% | ABOVE |
| 150 SMA | $6.39 | +50.53% | ABOVE |
| 200 SMA | $5.64 | +70.44% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is ARTV in an uptrend right now?
ARTV has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, ARTV is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is ARTV overbought or oversold?
ARTV's RSI (14) is 51. The stock is in neutral territory, neither overbought nor oversold.
Is ARTV outperforming the market?
ARTV has a Relative Strength (RS) Rating of 91 out of 99. Yes, ARTV is a market leader, outperforming 91% of all stocks over the past 12 months.
Where is ARTV in its 52-week range?
ARTV is trading at $9.62, which is 66% of its 52-week high ($14.53) and 62% above its 52-week low ($1.48).
How volatile is ARTV?
ARTV has a Beta of 2.03 and 52-week volatility of 150%. It's more volatile than the S&P 500 - expect bigger swings.